Jeremy Kortmansky is an Oncology physician affiliated with Yale Cancer Center. OpenAlex indexes 88 publications with 3,337 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2080 Whitney Ave
Suite 240
Hamden, CT 065183600
Telephone
203-407-8002Registry record last updated 28 Jan 2013.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- Daiichi Sankyo Inc.Program year20231 payment
- Merck Sharp & Dohme LLCProgram year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
60.2%Serotonin-3 Receptor Antagonist23.7%Ondansetron Odt100%Part D≥40 patientsOpioid Agonist18.8%Loperamide100%Part D≥27 patients+ 2 more classes in this area
Nervous system
15.6%Benzodiazepine9.1%Lorazepam100%Part D<11 patientsOpioid Agonist6.5%Oxycodone Hcl100%Part D≥11 patientsBlood & clotting
14%Salt solutions14%Sodium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
Journal of Clinical Oncology
2024 - A Phase 2 study of Savolitinib in Patients with MET Amplified Metastatic Colorectal Cancer
Journal of Gastrointestinal Cancer
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Ian Krop, MD
Yale Cancer Center
Harriet Kluger, MD
Yale Cancer Center
Stephanie Halene, MD
Yale Cancer Center
John Kunstman, MD
Yale Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”